OVERVIEW

EyeGate is a clinical stage pharmaceutical company focused on developing and commercializing products for treating diseases and disorders of the eye by leveraging two proprietary platform technologies, the crosslinked hyaluronic acid (CMHA-S) and iontophoresis drug delivery platforms.

PROPRIETARY TECHNOLOGY PLATFORMS

CMHA-S Platform

Platform based on modified hyaluronic acid (HA); specifically crosslinked thiolated carboxymethyl HA

HA-based biomaterials have protective and lubricating properties, are non-immunogenic, and have been shown to play a role in derm, joint and ocular wound management

First product in the clinic is an eye drop formulation (OBG)

Ocular Bandage Gel (OBG) Eye Drop

OBG is a preservative-free, high concentration (0.75%) eye drop that resists degradation and adheres to the ocular surface without blurring vision

OBG has significant shear thinning properties, which allows for a more viscous barrier at low shear rates as in a resting tear film

OBG will be the only Rx HA eye drop in the U.S. and is the purest solution of HA available with only 3 ingredients: water, crosslinked HA, and PBS (phosphate buffered saline)



Regulatory

OBG has a device "mechanical" mode of action, as it is neither metabolized nor chemically altered in vivo after application to the ocular surface

There is no predicate device – this is the first prescription HA eye drop in the U.S. and FDA has agreed to the 510(k) de novo pathway. Meeting with FDA (Devices) in March/April 2019 to confirm OBG is ready for a de novo submission

Broad Market Opportunity for OBG

Over 60 million potential patients with corneal wounds or epitheliopathies in the U.S.

OBG Clinical Trials

OBG has been evaluated in 3 well-controlled clinical studies. This includes 2 studies in post- photorefractive keratectomy (PRK) patients and 1 in subjects with punctate epitheliopathies (PE)

PRK: OBG outperformed the standard of care, bandaged contact lens, in both PRK studies.

Positive data in the EYEG-033 study confirms results from first EYEG-031 study.

	Number of Healed Eyes using OBG vs. Standard of Care				Ocular Bandage Gel: % Better and Standard of Care		
	Group 1 (N = 15)	Group 2 (N = 15)	Control Group (N = 15)		Group 1 (N = 15)	Group 2 (N = 15)	Control Group (N = 15)
Day 3	11	13	10	Day 3	73.3%	86.7%	66.7%
Day 4	15	15	13	Day 4	100.0%	100.0%	86.7%

Punctate epitheliopathies (e.g. dry eye): OBG demonstrated a fast onset of action with statistically significant improvement in symptoms using the SPEEDTM questionnaire at Day 7 over the control arm. Statistically significant symptom improvement continued ongoing through Day 28 with an improvement of 30% from baseline versus 4% for the control.





The cornea is responsible for 65–75% of the eye's total focusing power. Disturbances at the central optical zone of the cornea cause visual performance to decrease/deteriorate. Also has a high density of nerve endings. OBG showed maximum improvement in staining at Day 14 or 40% vs 23% for rewetting drops. Improvement of 30% vs. 14% for the rewetting drops seen at Day 7. Combined = both eyes.

IONTOPHORESIS PLATFORM – EYEGATE® II DELIVERY SYSTEM

Proprietary technology, the EyeGate® II Delivery System, utilizes the Iontophoresis Platform, a non-invasive method of propelling optimal therapeutic levels of drug into the eye

A. Applicator
B. Small electrical current at electrode
C. Charged drug product (in applicator)
D. Active product propelled into the eye
E. Eye receiving drug product noninvasively

Dose is controlled by current strength and application time



Management Team

Stephen From, President and Chief Executive Officer
Barbara Wirostko, M.D., Chief Medical Officer
Sarah Romano, Chief Financial Officer
Michael Manzo, Vice President of Engineering
Brenda Mann, Ph.D., Vice President of R&D
Lisa Brandano, Vice President of Clinical Operations

Contact Us

Joseph Green
Edison Advisors Investor Relations
Tel: (646) 653-7030
E-mail: jgreen@edisongroup.com

NASDAQ: EYEG
Share Price | Market Cap | 52-Week Range
$0.520 $22.4M $0.275-$1.34*
**Metrics as of 01/10/19*